^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Iomab-B (I-131-apamistamab) (α radiation emission, CD45-targeted antibody- radioimmunoconjugate conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
469 131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML
Published date:
11/02/2023
Excerpt:
For TP53 mutation positive pts who received 131I-apamistamab (131I-apamistamab plus CO pts), the median OS was 5.49 mos compared to a median 1.66 mos in pts who did not receive 131I-apamistamab (CC pts without CO) [(HR=0.23; 95% CI [0.10, 0.52]; p=0.0002)....131I-apamistamab led alloHCT significantly improves survival outcomes in pts with TP53 mutations....These data clearly support the use of 131I-apamistamab led induction and conditioning and alloHCT in R/R AML, including in patients with a TP53 mutation...
Trial ID:
